Justin Chakma insider trades: ARS Pharmaceuticals (SPRY) stock sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Justin reports to the SEC
Open-market buys and sales
6 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Nov 12, 2025 | SPRY | ↓ Sell | 166,380 | $8.87 | $1.5M | Direct | Nov 14, 2025 (2d) |
| Dec 13, 2024 | SPRY | ↓ Sell | 144,605 | $12.23 | $1.8M | Direct | Dec 13, 2024 (0d) |
| Dec 10, 2024 | SPRY | ↓ Sell | 50,000 | $13.15 | $658K | Direct | Dec 12, 2024 (2d) |
| Dec 6, 2024 | SPRY | ↓ Sell | 144,640 | $14.11 | $2.0M | Direct | Dec 6, 2024 (0d) |
| Dec 3, 2024 | SPRY | ↓ Sell | 90,000 | $13.43 | $1.2M | Direct | Dec 4, 2024 (1d) |
| Nov 27, 2024 | SPRY | ↓ Sell | 100,000 | $14.12 | $1.4M | Direct | Nov 27, 2024 (0d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other SPRY insiders
Open-market trades in the last 12 months
About Justin Chakma's insider trades
Justin Chakma is Chief Business Officer at ARS Pharmaceuticals (SPRY). Since Nov 27, 2024, Justin has reported no open-market purchases and 6 sales worth $8.6M on SEC Form 4. In the last 12 months: 1 sale ($1.5M).
Their filings also include grants and awards (5 filings), option exercises (5 filings). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every SPRY insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.